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1. Introduction 
Amyloid is an eosinophilic substance which appears “apple-green birefringence” in Congo 
red stained tissue sections under polarized light. This standard histological analysis is 
supported with immunochemistry technic using specific antibodies directed against most of 
the common human amyloid proteins, and also amyloid proteins can be identified with 
characteristic fibrillar appearance by electron microscopy (1). 
Amyloidosis is a name given to a heterogenous group diseases. It is caused by the 
extracellular amyloid deposition as insolubl fibrillar aggregates that destroy normal tissue 
architecture and interfere normal function of tissues and organs. The biochemical nature of 
the precursor protein forming the amyloid fibrils differs in the different clinical conditions 
such as chronic inflammatory infectious or non-infectious diseases, malignancies, hereditary 
diseases and other less common disorders. Identification of the type of amyloidosis is 
important to assess clinical management, prognosis and treatment. Amyloid fibril protein 
nomenclature “2010 recommendations of the nomenclature commitee of the International 
Society of Amyloidosis“ was reported and 27 human fibril proteins were described. In 
current nomenclature, a prefix “A” shows amyloid, followed by an abbreviation orginated 
from the name of the precursor protein (for example, AL addresses amyloid derived from 
immunglobulin light chain, AH shows amyloid derived from immunglobulin heavy chain, 
AA indicates amyloid derived from serum amyloid A (SAA) protein, Aß2M shows amyloid 
orginated from ß2 microglobulin, ATTR describes amyloid derived from transthretin, and 
others). The amyloidoses can be classified according to localized or systemic deposits along 
with its biochemical nature (2). 
Localised amyloid depositions usually lead to mechanical interference and generally are 
considered to be benign. Alzheimer’s disease is the only form of localized amyloid fibril 
deposition which often leads to serious disorder. 
Systemic amyloid forms include mainly immunoglobulin light chain (AL) amyloidosis, 
secondary, reactive (AA amyloidosis), hereditary familial form (for example, ATTR 
amyloidosis) and dialysis-related (Aǃ2M) amyloidosis (3,4). AA, AL and ATTR amyloidosis 
involve more than 90% of systemic amyloidosis (5).  
AL amyloidosis is the most common form of systemic amyloidosis in western world. The 
ratio AL/AA amyloidosis appears 2/1 in the Netherlands (6). A retrospective study from 
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France suggests a 3/1 AL/AA ratio (7). These ratios should be supported by prospective 
studies in the world. AL amyloidosis is caused by clonal plasma cells that produce 
misfolded light chains, associated with B cell lymphoproliferative diseases such as multiple 
myeloma, and rarely malignant lymphoma and macroglonulinemia. Cardiac involvement is 
main clinical characteristic of AL amyloidosis (8). Demonstration of a monoclonal 
immunoglobulin (Ig) protein in the blood, in urine, or in clonal plasma cells in the bone 
marrow is an important finding for the diagnosis. 
AA amyloidosis is the second most common type of amyloidosis worldwide. Acquired and 
hereditary diseases can cause to AA amyloidosis, including chronic inflammatory diseases, 
such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), familial Mediterranean 
fever (FMF) or other periodic fever syndromes, bronchiectasis, tuberculosis, chronic 
osteomyelitis and rarely malignancies. The prevalence rates of AA amyloidosis in these 
disorders show the wide variations due in part to geographic differences, possibly genetic 
factors, and also according to the methods of the resarch performed by the native biopsies or 
postmortem studies. The underlying inflammatory disease is usually longstanding and 
characterized with persistent inflammation. Renal involvement is the major cause of 
morbidity and mortality in AA amyloidosis (9).  
Hereditary amyloidosis occurs by deposition of genetically variant proteins and it is 
associated with mutations in the genes such as transthyretin, apolipoprotein AI, 
apolipoprotein AII, apolipoprotein AIV, lysozyme, fibrinogen A, gelsolin, cystatin C. The 
transthyretin amyloidosis is the most common form of hereditary amyloidosis, and consists 
in two varieties; as “senil” and hereditary. Clinic characteristics are polyneuropathy and 
cardiac involvement, and renal involvement may be clinically silent (10).  
This review includes the following issues: (1) epidemiology and incidence of the underlying 
diseases related AA amyloidosis, (2) the clinical manifestations of the involved 
tissues/organs, and (3) diagnostic approach and treatment strategy in AA amyloidosis.  
In AA amyloidosis (secondary, reactive), amyloid fibril proteins are composed of fragments 
of serum amyloid A (SAA) protein, a major acute-phase reactant protein, an apolipoprotein. 
Its serum concentration increases 100 to 1000-fold under inflammatory signals, 
predominantly interleukin (IL)-I ǃ, tumor necrosis factor (TNF)-α and IL-6. In chronic 
inflammatory diseases, persistent or intermittent elevated SAA concentrations are the basic 
factor promoting amyloidosis (9). Increased SAA levels were showed to be correlate to 
disease course in patients with amyloidosis. Also the increased amyloid load and 
deteriorated organ function were demonstrated to be associated with persistently high SAA 
concentration (>50m/L) (11). However, amyloidosis does not develop in every patient with 
chronic active inflammatory diseases, only a subset of patients with persistently increased 
SAA levels may develop AA amyloidosis. Several forms of SAA have been identified in 
human plasma, SAA1 seems a predominate factor in the formation AA deposits. The genetic 
factors may increase the risk of amyloidosis, but it is not fully clear. The main suspects focus 
on the genes of the SAA1 protein, however there are differences related to ethnicity (12-14). 
The frequency of the SAA1.3 allele is about 40% for Japanese, it is lower in whites (15). It 
was reported that the SAA1.3 allele is a risk factor for the association of AA amyloidosis and 
alsoa poor prognostic factor in survival for Japanese patients with RA (16). 
Environment can affect onset of amyloidosis in chronic inflammatory disease. Toitou et al. 
suggested that country of recruitment is an important factor for the development of renal 
amyloidosis in FMF and authors suggested that the patient’s country should be considered 
(17). 
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2. Epidemiology and incidence of underlying diseases due to AA 
Amyloidosis 
AA amyloidosis occurs in association with chronic infectious (i.e. tuberculosis, bronchiectasis, 
osteomyelitis, leprosy) and chronic inflammatory diseases (i.e. RA, JIA, AS, IBD, psoriatic 
arthritis, Behçet’s disease, adult Still’s disease), malignancies (i.e.Hodgkin’s disease, renal 
carsinoma, Castleman’s tumor) and hereditary periodic fever (i.e. FMF, others). The 
prevalence rates of AA amyloidosis in these disorders show a wide variation due in part to 
geographic differences, possibly genetic factors, and also according to the study’s material 
(i.e. biopsy or autopsy) and method (i.e. immunohistochemistry).  
AA amyloidosis associated with chronic infections such as tuberculosis and osteomyelitis 
was common in early 20th century. These cases appear less frequent after the eradication of 
some infectious diseases and due to advances in the management of diseases. Von Hutten et 
al. reassesed renal amyloidosis in 233 renal biopsies and demonstrated that chronic non-
infectious inflammmatory diseases were more than chronic infectious diseases (73.8%, 24.6% 
respectively) (18). Similar results were found in the Western countries (19,20). Malignancy 
related AA amyloidosis is rare causes. Among malignities renal cancer, hepatocellular 
carcinoma and lymphoma are most frequently implicated in AA amyloidosis. Castleman's 
disease is one of the most recently recognized causes in case reports (21).  
Rheumatoid arthritis is one of non-infectious, inflammatory, longstanding rheumatic 
disases. It is generally an inflammatory disease in synovial joints, and also affects systemic 
organs including lungs, heart, kidneys, nervous system. A major factor responsible for the 
development of AA amyloidosis seems sustained overproduction of SAA under chronic 
inflammatory conditions. The prevalence of AA amyloidosis in RA is a range from 7% to 
26% and it varies due to clinical severity of patients and duration of arthritis (22-24). In a 
Dutch series, RA was the most frequent cause of AA amyloidosis, followed by recurrent 
pulmonary infection (11%), Crohn's disease (5%), ankylosing spondylitis (5%), tuberculosis 
(3%), osteomyelitis (2%), FMF (2%) and Hodgkin's disease (2%) (25). A study from Finland 
(26) based on Finnish Registry for Kidney Diseases identified 264 patients suffering from 
amyloidosis associated with RA, AS or JIA over the period 1995-2008, most of cases were RA 
(n=229), followed JIA (n=20) and AS (n=15). A cohort study of patients with RA showed 
16.3% AA fibril depositions in the abdominal fat samples of patients (27). 
In general, the development of AA amyloidosis in RA takes a long time, often more than 15 
years (28,29). Morigush et al. reported that secondary amiloidosis developed in a shorter 
period in Japanese RA patients with the Ǆ/Ǆ homozygotes in the SAAI gene (14).  
Juvenil idiopathic arthritis is also a cause of AA amyloid which has been observed in 
systemic (Still disease) and polyarticular forms (30). However, the effective suppression of 
the disease activity with new immunosuppressive treatment agents (i.e.biologics) in early 
stages may change prognosis in both RA and JIA.  
AA amyloidosis also complicates 4 hereditary diseases with varying frequencies: FMF, the 
tumor necrosis factor receptor–associated periodic syndrome (TRAPS), Muckle-Wells 
syndrome (MWS) and hyperimmunoglobulinemia IgD with periodic fever (HIDS) (31).  
Familial Mediterranean fever is well recognised among the hereditary periodic fever 
syndromes, also called as autoinflammatory syndromes. Autoinflammatory diseases are 
characterised by unprokoved inflammatory episodes without any recognizable pathogens. 
FMF mainly affects people of Mediterranean origin (Sephardic Jews, Turks, Armenians, 
Araps). Its prevalance is between 1/500-1/1000 and carrier rate is very high in the Eastern 
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Mediterranean (32). Its a monogenic autoinflammatory disease associated with mutations in 
a gene called MEFV (MEditerranean FeVer) (33,34).  
There are two phenotypes of FMF as types 1 and 2. Familial Mediterranean fever type 1 is 
characterised by recurrent short episodes of fever, peritonitis, synovitis, pleuritis, rarely 
pericarditis or erysipelas-like skin disease, along with increased acute phase reactants. 
Familial Mediterranean fever type 2 is probably quite rare characterized by amyloidosis as 
the first clinical manifestation of FMF without classical FMF attacks, but their family 
members have often characteristic FMF signs (35,36). 
The symptoms and severity of FMF vary among affected individuals. During attacks,acute 
phase reactants such as C-reactive protein, fibrinogen, ceruloplasmin, serum amyloid A are 
elevated. After attacks, all these abnormal tests usually return to normal values. In %30-63 of 
patients, inflammation can persist in attack-free periods with elevated acute –phase proteins 
(37-39). Chronic subclinical inflammation can cause the risk of developing complications 
such as AA amyloidosis. 
In a retrospective analysis of 287 patients with renal amyloidosis from Turkey, FMF appears 
most frequent among the causes of AA amyloidosis, the etiological distribution was found 
as follows; FMF 64%, tuberculosis 10%, bronchiectasis and chronic obstructive lung  
disease 6%, RA 4%, spondyloarthropathy 3%, chronic osteomyelitis 2%, miscellaneous 4%, 
unknown 7%. Oedema accompanied by proteinuria was the most prominent presenting 
finding in 88% of the cases. Hepatomegaly in 17%, and splenomegaly in 11% of the patients 
were found in this study (40). In pediatric FMF series, 29% of 110 cases developed AA 
amyloidosis (41). In Sephardic Jews, the incidence of FMF related amyloidosis was 37.2 % 
(42). The frequency of amyloidosis varies among different ethnic groups and also due to 
regular the use of colchicine which is beneficial in preventing FMF amyloidosis by a 
reduction in the number and severity of attacks. 
The mutations in exon 10, in the region between 680 and 694 and especially M694V 
homozygosity were demonstrated to be associated with AA amyloidosis (43-45), however 
the different mutations were also shown (46). M694V homozygosity and/or SAA 
alpha/alpha genotype, male gender,delay in diagnosis of FMF and the presence of 
secondary amyloidosis in the family has been suggested to be risk factors for the 
development of amyloidosis in FMF patients (43-47). The frequency of the main signs and 
symptoms of FMF were found fever 92.5%, peritonitis 93.7%,arthritis 47.4%, pleurisy 31.2%, 
amyloidosis 12.9% (44).  
TRAPS is a rare autosomal-dominant disorder characterised by recurrent attacks of fever, 
abdominal pain, rash and periorbital edema. AA amyloidosis is more common among 
patients with cystein mutations compared to non-cystein ones (48).  
MWS is also autosomal dominant disease, characterised by recurrent attacks of urticaria, fever, 
polyarthralgia. Amyloidosis may develop in later life (49). It was estimated that approximately 
one-third of patients suffer from amyloidosis and there is familial clustering (50).  
Hyperimmunglobulin D syndrome is an autosomal recessively inherited disease manifested 
by recurrent attacks of fever, arthralgia, abdominal pain, diarrhea, maculopapular rash, and 
lymphadenopathy lasting 3-7 days. The incidence of amyloidosis in hyper IgD syndrome is 
remarkably low compared to other periodic fever syndromes.  
Secondary amyloidosis in ankylosing spondylitis is less frequent. Sing et al. detected that 
subclinical amyloid deposits by abdominal subcutaneous fat aspiration in 5 patients ( 7%) 
with ankylosing spondylitis (n= 72) with disease duration longer than 5 years (51). 
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In other chronic rheumatic inflammatory diseases including systemic lupus erythematosus, 
polymyalgia rheumatica and Behçet’s disease, AA amyloidosis has been rarely reported in 
case reports (52-59). 
The development of AA amyloidosis was reported in 28 SLE patients (one of them 
overlapping with systemic sclerosis) between 1956-2011 (up to March, based on Pubmed). 
The lack of acute phase response in SLE compared to other inflammatory diseases  
has contributed to reduce the incidence (52-54). Most of patients presented 
proteinuria/nephrotic-range proteinuria or nephrotic syndrome or progressive renal 
insufficiency when the amyloidosis was diagnosed. Renal failure was a major cause of death 
of these patients. Cardiac presentations with arrthmia and congestive heart failure in SLE 
related AA amyloidosis is not common. Hepatic, splenic pulmoner, intestinal, adrenal 
involvement with amyloidosis and mononeuropathy were very rare in SLE patients (54).  
Behçet’s disease is a multisystem inflammatory disorder with a genetic background, 
characterised by oral and genital ulcers, uveitis, cutaneous pustular erythematous lesions, 
arthritis, central nerveous system involvement and/or vascular manifestations such as 
veneous thrombosis, arteritis and aneurysms. Behçet’s disease is more frequent in the 
regions along the Mediterranean, Middle East and Far East countries. Amyloidosis is a rare 
complication, its frequency changes between 0.01 and 4.8 % in several clinical series (57). 
Major risk factors for the development of AA amyloidosis are peripheral or pulmonary 
arterial involvement and venous thrombosis, and the presence of arthritis has also been 
implicated as a predictor in Behçet’s disease (58-59).  
Secondary amyloidosis rarely occurs in long-lasting inflammatory bowel diseases. In the 
retrospective studies the prevalance is ranging from 0.5% to 3% among patients with 
Crohn’s disease (60,61). 
3. Clinical manifestations of AA Amyloidosis 
Clinical amyloidosis is defined as the presence of symptoms or signs of visseral involvement 
by amyloid. General signs such as fatique and weight loss are often. Clinical signs of 
amyloidosis generate according to its locations, and most of them are not specific. Kidney, 
liver, spleen, heart, intestinal and respiratory tract are the main involved organs or systems 
in AA amyloidosis (4,19,20,55,60-66). Adrenal and thyroid glands, testes, skin, synovial 
membrane and bone marrow are other sites of involvement and less common presentations 
(67-69). Most of clinical symptoms are caused by distortion of the normal tissue architecture. 
The patients can present with organ enlargement such as hepatomegaly, splenomegaly, 
renomegali, enlarged thyroid, rarely hypertophy of lymph nodes by massive amyloid 
deposition, easy bruising by weakening of the vascular walls (65,70), proteinuria, renal 
failure and malabsorbtion (4,19,20,61,65). Unexplained kidney, heart, or systemic disease, 
hepatomegaly and splenomegaly are among suspicious for amyloidosis. 
In AA amyloidosis, kidney is the most affected organ (4). The first sign of renal amyloidosis 
is asemptomatic proteinuria, gradually progressing to nephrotic syndrome and /or renal 
dysfunction. Amyloidosis is one of the major differential diagnoses of proteinüria. The most 
common clinical manifestation is peripheral edema due to the development of nephrotic 
syndrome. Haematuria, renal vein thrombosis and tubuler defects are very rare. Hematuria 
reflects amyloid deposition anywhere in the genitourinary tract. The blood pressure may 
often remain normal. It is not clear that development of hypertension in renal amiloidosis 
whether due to renal involvement or a coincidental finding. Persistent nephrotic syndrome 
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and advanced renal insufficiency and enlarged kidney suggest amyloidosis. Occasionally 
the kidneys are small and scarred. Rarely, a sudden onset of acute renal failure may occur 
due to renal vein thrombosis. It is very rare for the presenting symptoms to be those of 
chronic renal failure. AA amyloidosis usually progresses toward end- stage renal failure 
which is the main cause of mortality. 
Amyloid deposits can occur in the mesangium, glomerular capillary loops, tubulo-
interstitium, and vasculature of the kidney. It was showed that the patients having glomerular 
amyloid deposition are more common and have a poor prognosis than patients having 
vascular and tubular amyloid deposition in secondary amyloidosis to RA (63). 
Once the disease established, prognosis remains poor. Renal failure and low serum albumin 
levels are the most important predictors for poor prognosis (19). Survival of patients with 
AA amyloidosis appears greatly improved as compared to past decades. Torregrosa et al. 
reported in a group of patients a survival of 67% and 53% at 12 and 24 months without 
dialysis respectively (64). Amyloidosis without therapy usually progresses to end-stage 
kidney disease. Progression of renal amyloidosis can be delayed or slowed by treatments 
that reduce the production of amyloidogenic precursor proteins, deposits may also regress. 
Hepatic involvement is usually expressed as hepatomegaly and increased in serum alkaline 
phosphatase levels. However, hepatic amyloidosis may remain asymptomatic for a long 
time or show only mild liver enzymes abnormalities. In the differantial diagnosis in patients 
with long-standing inflammatory disease, hepatomegaly and liver function tests 
abnormalities hepatic amyloidosis should be considered. Some complications such as portal 
hypertension, jaundice, ascites are rare. Gioeva et al. retrieved all liver biopsies from a series 
of 588 cases with histologically confirmed amyloidosis and reported that hepatic 
amyloidosis is most commonly AL amyloid of lambda- and kappa-light chain origin (87%). 
Hepatic AA amyloidosis was found in a single patient (2%) in this study (71). 
The spleen is affected and splenomegaly is seen in early periods, functional hyposplenism 
and splenic rupture rarely may develop(66).  
Gastrointestinal amyloidosis manifestations such as abdominal pain, vomiting, disphagia, 
diarrhea, malabsorbtion, obstruction, bleeding, perforation may occur in about 20% of 
patients (65), these symptoms are largely nonspecific. The rectum is a commonly affected 
site and rectal biopsy is the initial diagnostic tool. The hypoproteinemia may not only be 
due to proteinuria but also to a decreased rate of protein synthesis as a consequence of 
hepatic amyloidosis, and also to malabsorption of amino-acids because of amyloid 
infiltration in intestinal mucosa. 
Heart disease in secondary amyloidosis is less common (<10%) than it is in other types of 
amyloidosis and is the main cause of death. Cardiac involvement has been associated with 
myopathic syndrome and coronary vascular syndrome. Arrithmias may occur at any time. 
Cardiac amyloidosis should be suspected in any patient who presents with restrictive 
cardiomyopathy, prominent signs of right-sided heart failure or left sided heart failure in 
the absence of ischemia disease. Valvular disease, pericarditis, systemic arterial emboli are 
rare. The combination of clinical and echocardiographic findings suggest amyloidosis (9).  
The involvement of adrenal glands may cause adrenal insufficiency. The involvement of 
thyroid may lead to hypotyroidsm. Although microscopic amyloid deposition may be 
demonstrated in thyroid gland, a significant enlargement of thyroid and its dysfunction are 
not often, goiter as a first evidence of AA amyloidosis is rarely seen and thyroid function 
tests are usually in normal limits. Enlarged thyroid gland making pressure to the near 
tissues and leading operation is a rare condition in systemic amyloidosis associated with 
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inflammatory disease. Bleeding is an important complication in thyroid operation of 
patients with secondary amyloidosis (66,70).  
Pulmonary amyloidosis is uncommon (72) and presents with cough, hemoptysis and 
dyspne. Amyloid depositions may find in bronchial, mediastinal and alveolar area and 
interferes with tumor mass. 
Skin involvement can present with petechiae, purpura and ecchymoses. Rarely papules, 
nodules, plaques can be seen.  
Arthritis is associated with febril attacks in patients with FMF. The patients with MWS  
patients have polyarthralgias accompanying urticaria. 
Spinal cord lesions and cranial nerve involvement are uncommon. Peripheral neuropathy or  
carpal tunnel syndrome occasionally may occur during the course of AA amyloidosis. 
Uretral and bladder amyloidosis are rare and present with pain and hematuria. Amyloid 
deposits in the wall of blood vessel may lead to vascular fragility, impaired hemostasis, and 
bleeding (70). Amyloid fibrils can also accumulate in the bone marrow (68).  
4. Diagnostic approach of AA Amyloidosis 
The approach of the diagnosis based on clinical mainifestations, clinical examination, 
biochemical nature of AA amyloidosis for differentiation with respect to other varieties, 
biochemical tests and genetic analysis. Clinical examination and evaluation of the various 
signs described above should be sistematically performed. The diagnosis of amyloidosis 
should be confirmed by biopsy from suspicious tissue (s) such as kidney, intestine, liver, 
thyroid, skin, bone marrow and endomyocard. If biopsy could not be taken from these 
tissues or clinical signs are not present, biopsy may be taken from intestinal mucosa (rectal), 
abdominal subcutaneous fat tissue, labial salivary gland samples. The results of 
gastrointestinal biopsy are highly corelated with those of renal biopsy but the results of 
abdominal fat samples are not (73). 
Abdominal fat aspiration biopsy is easy to perform and repeatable. However, fat aspiration 
biopsy is less sensitive than kidney and rectal biopsy. Labial salivary gland biopsy is now 
replaced the old gingiva biopsy. Endomyocardial biopsy can be needed in cardiac 
involvement. The aim is to detect amyloid early and to type it correctly. 
Congo red stain is the gold standard for amyloid detection. The amyloid type must be 
identified based on amyloid protein within the deposits by immunohistochemistry or 
immunoelectronmicroscopy and Western blotting. AA amyloidosis can also be diagnosed 
using serum amyloid P component scintigraphy (74).  
5. Treatment strategy of AA Amyloidosis 
The main therapeutic target of the chronic inflammatory diseases is to suppresse the 
inflammatory activity of the underlying disease and to prevent the development of AA 
amyloidoisis. The concentration or production of SAA is reduced by the treatment of 
underlying chronic inflammatory rheumatic diseases including anti –inflammatory drugs, 
immunosuppressants or biologics. Treatment with corticosteroids and immunosuppressive 
drugs in mainly RA and JIA have proved the suppression of the underlying inflammatory 
process (26). It is suggested that immunosuppressants can improve prognosis of patient 
with AA amyloidosis (75). Each patient requires systematically evaluation to determine their 
optimal treatment. Earlier and powerfull treatments of underlying diseases should be aimed.  
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Colchicine is the most effective drug for prevention of acute inflammatory attacks and 
development of amyloidosis in most patients with FMF. Early treatment of amyloidosis is 
associated with much better prognosis and survival, but even reverse established deposits. 
Colchicine dose of 1.5-2 mg daily is necessary for prevention of the progression of 
amyloidosis (76). It was shown that colchicine can reduce proteinuria in patients with renal 
amyloidosis of FMF by case series (77,78). 
Epradisate (anti-amyloid compounds) for treating with AA amyloidosis which leads a 
significant delay in the progression to dialysis or end-satge renal disease (79,80). 
In recent years, new biological therapies were approved for the treatment, especially in 
patients with RA, JIA, spondyloarthropathy, who is unresponsive to conventional treatment. 
Several isolated cases and small series have demonstrated a marked clinical improvement 
and complete or partial resolution of AA amyloid deposits in patients with RA,JIA, 
herditary periodic fever syndromes under these agents (81-90). 
Anti-cytokine biologicals including TNF-alpha antagonists (infliximab, etanercept, 
adalimumab) (81-84) and a humanised IL-6 R antibodies (tocilizumab) suppresse strongly 
SAA production by liver and also inflammatory process (85-87). These biologics have been 
reported to be highly effective in patients with AA amyloidosis secondary to RA and JIA. 
IL-I receptor antagonist (anakinra) showed a persisted effect in patients with familial cold 
autoinflammatory syndrome (88-89).  
The trial of rituximab ( anti-CD 20 monoclonal antibody) was reported the effficacy for a few 
patients with AA amyloidosis secondary to RA (91).  
A new class of antiamyloid agents, currently in clinical trials, also appear to be amyloid type 
for AA and ATTR (92).  
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